Forbion European Acquisition Corp.

Sander Slootweg leads the SPAC as CEO while Jasper Bos serves as CIO; both are managing partners at the sponsor, Forbion, and draw on the parent firm's 50-plus investment professionals for deal origination. The partnership group collectively screens European biotech targets that fit the late-stage clinical or commercial threshold required for a business combination. Their investment committee process mirrors Forbion's venture underwriting standards, not a typical SPAC sponsor's lighter diligence model.

The vehicle benefits from Forbion's existing venture portfolio and proprietary European deal flow, which spans over two decades of exclusive life-science investing. Rather than a sponsor team pivoting into biotech for a single transaction, Forbion European Acquisition Corp. screens targets that have already crossed the parent firm's radar through venture co-investments, board seats, or advisory relationships. This embedded access reduces the cold origination problem that plagues most blank-check vehicles hunting in a specific sector.

Forbion European Acquisition Corp. is a publicly listed blank-check vehicle sponsored by Forbion, the Netherlands-headquartered VC firm managing over €3 billion across early-stage and growth-stage life sciences funds. The SPAC shares senior leadership with the parent firm and draws on its investment team, but the trust account and public shareholders are structurally separate from the venture limited partners. A future business combination would create a standalone public company distinct from Forbion's fund structures.

The mandate explicitly focuses on European biotech or pharmaceutical companies with assets in late-stage clinical development or early commercialization. This stage focus distinguishes the SPAC from Forbion's early-stage venture funds, which frequently invest at Series A or Series B in preclinical or Phase I-stage companies. The SPAC seeks targets with de-risked regulatory pathways and near-term commercial catalysts.

The vehicle is explicitly mandated to pursue targets headquartered or primarily operating in Europe, leveraging the sponsor's established origination networks across the Netherlands, Germany, the United Kingdom, and other European biotech hubs. While the parent firm has invested globally through some co-investment structures, the SPAC's trust agreement limits the search to European-domiciled entities with significant continental operations.